References
- Meadows AJ, Stephenson N, Madhav NK, et al. Historical trends demonstrate a pattern of increasingly frequent and severe spillover events of high-consequence zoonotic viruses. BMJ Glob Health. 2023;8(11):e012026. doi: 10.1136/bmjgh-2023-012026.
- SOE Epidemiology Bulletin. “Fatal Alaskapox Infection in a Southcentral Alaska Resident” No. 2, Feb 9, 2024. Available from: https://github.com/fbranda/alaskapox/blob/main/bulletins/b2024_02.pdf.
- Springer YP, Hsu CH, Werle ZR, et al. Novel orthopoxvirus infection in an Alaska resident. Clin Infect Dis. 2017;64(12):1737–1741. doi: 10.1093/cid/cix219.
- Alaska Division of Public Health. Frequently asked questions about Alaskapox virus. Available from: https://health.alaska.gov/dph/Epi/id/SiteAssets/Pages/Alaskapox/Alaskapox-FAQ.pdf.
- Merchlinsky M, Albright A, Olson V, et al. The development and approval of tecoviromat (TPOXX®), the first antiviral against smallpox. Antiviral Res. 2019;168:168–174. doi: 10.1016/j.antiviral.2019.06.005.
- Grosenbach DW, Honeychurch K, Rose EA, et al. Oral tecovirimat for the treatment of smallpox. N Engl J Med. 2018;379(1):44–53. doi: 10.1056/NEJMoa1705688.
- Quenelle DC, Buller RM, Parker S, et al. Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob Agents Chemother. 2007;51(2):689–695. doi: 10.1128/AAC.00879-06.
- Painter GR, Bowen RA, Bluemling GR, et al. The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection. Antiviral Res. 2019;171:104597. doi: 10.1016/j.antiviral.2019.104597.
- Gigante CM, Gao J, Tang S, et al. Genome of alaskapox virus, a novel orthopoxvirus isolated from Alaska. Viruses. 2019;11(8):708. doi: 10.3390/v11080708.
- Borsetti A, Scarpa F, Maruotti A, et al. The unresolved question on COVID-19 virus origin: the three cards game? J Med Virol. 2022;94(4):1257–1260. doi: 10.1002/jmv.27519.